We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Leistertheinvestor, thanks for the polite and measured response. Not that I would tell people how to invest it is good to hear your thoughts as I highly respect them.
Enjoy the weekend and let’s hope the ‘make a quick buck investors’ have gone and the serious one start coming!
I’m invested in Nuvec and still hold a 7 figure amount, I’m bullish on Nuvec delivery nucleic acids and I love the business model. What I’m not a fan of is the way the BOD brought up another potential revenue stream and allowed investors to constantly view this online without an update, wonder how many invested solely into the ex-vivo gene therapy potential? I actually added more on the strength of this, and they’ve only just disclosed the bad news this week because it was legal to do so! At what point did they know it wasn’t a viable route?
I took £32k on Monday and sold them for a few hundred quid profit which I’m holding until I get news on dispersion.
We currently have the covid works as our ONLY near term hope at collaborating with a developer, if dispersion comes back delayed or not improving we’re going to fall, same goes for oral administration (assuming they ain’t shelving that too)..
Apologies for the change of tone, I’m not de-ramping just sharing my dissatisfaction with the way the money was raised.
Leistertheivestor, your message does surprise me. I had to go back over your history as I always thought you were fairly bullish and looking you certainly have been.
What you are talking about it old news. The way I see it was Covid was just starting to take hold so they changed their plans to test Nuvec on it. Surely with all the coverage Covid was getting this made, and still does, makes sense. Yes, it was annoying with the placing but if it works this will fly.
Also you were topping up this week!?!
Just my opinion as you certainly know your stuff and disappointed to hear you selling
Quite a few investors are annoyed with with the Viral Vector element of the interims, the V V project has been shelved for the foreseeable future. This was introduced to us as a “New Nuvec Opportunity and patent filing”.. it stated,
"The global viral vector manufacturing market was valued at $273 million in 2017 and is expected to grow to $816 million by 2023. Sales of transduction reagents were estimated to be $68m in 2017 and growing to $123m by 2024.
"These are significant markets for in-vitro applications of Nuvec® and will allow us to look at additional commercial opportunities whilst we continue to develop our in-vivo data package for licensing Nuvec® as a delivery system for cancer treatments and vaccines.".
That was done the day after the AGM where Nigel stated there was a higher rate of news flow coming, as you can imagine there was significant new positions being taken and old investors loading up. He was asked in the Zoom “how’s the cash position?”, he stated “yeah, good!”.. three weeks later we had a placing.
It may be AIM and it may be common to act in this way but don’t expect the share price to climb when you start removing the opportunities that build the SP.
I’ve sold a fair amount over the last few sessions and will continue to sell on spikes, until the agglomeration results are released.
i quite liking the sp where it is, will take the opportunity to top up if the bid drops below 6. already doublked money, but can see this back at 10/12 soon.
No financial advice intended. - That is my opinion and something I am willing to invest.
GLA
MAX-Power, yes was a very good listen. He sounded very upbeat. Good that he covered of the Pre In Vivo study not being an issue, although if done properly in RNS there would have been no need to!
I would like some timeframes on the In Vivo study
A very bullish chat Nigel Theobald.
*Highlights- Dispersion and formulation of Nuvec
*Covid a great chance to expose the brand of the company
* continuation of the optimisation work - work to be completed shorted.
appointed new company for tec transfer
* Coronoa samples to e used to optimise Nuvec
*First experiment isn't a failure- didn't want to waste money- starihght into antibody study. - Good thing
*Nuvec work for all vacines.
3 very clear application- Massive commercial potential.
more... need to listen to understand his confidence - GLA